MoCo’s new COVID vaccine awaits approval, has protein base

MONTGOMERY COUNTY, MD – Novavax, Inc., a Gaithersburg-based biotech company that creates next-generation vaccines for serious infectious diseases, will supply the U.S. government with 3.2 million doses of the Novavax COVID-19 vaccine if it receives U.S. Food and Drug Administration Emergency Use Authorization and Centers for Disease Control and Prevention recommendation.

Novavax’s protein-based vaccine will be made available free of charge to states, jurisdictions, federal partner pharmacies and federally qualified health centers.

“We are excited to take a step closer to potentially offering our vaccine to physicians, healthcare organizations and consumers who have been waiting for a protein-based vaccine option,” said Stanley C. Erck, President. and CEO of Novavax.

The Novavax COVID-19 vaccine was created using Novavax’s recombinant nanoparticle technology to generate an antigen derived from the coronavirus spike protein and is formulated with Novavax’s patented saponin matrix adjuvant to enhance the immune response. The Novavax COVID-19 vaccine contains a purified protein antigen and cannot replicate or cause COVID-19, according to a company press release.

The vaccine was designed from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes the disease COVID-19.